Watertown, Massachusetts -- RNA pharmaceutical company Dicerna Pharmaceuticals has garnered $4 million in additional venture capital financing in its second round.
Dicerna is developing therapeutics based on Dicer substrate technology that makes use of the RNA interference mechanism.
SR One made the additional investment, which will be used to advance the company's in-house program in oncology. |